What We Do
Ignite Biomedical discovers algorithmic biomarkers that will enable the development and ultimately the commercialization of precision medicine to accurately inform individualized treatment decisions.
Product Discovery
Our organization invests in the discovery of algorithmic biomarkers and targets through the utilization of Evolutionary Computation through Emerge® – the only quantitative artificial intelligence platform in Biopharma proprietary to our Joint Venture partner Liquid Biosciences. It was specifically designed to analyze data from complex non-linear systems which produces transparent, unbiased, and accurate predictive algorithms. Standard biomarker AI tools utilized in the healthcare industry today have a 90%+ failure rate. To date, Emerge® has never experienced a validation failure. Emerge® is novel, fast, and extremely accurate. This has the potential to de-risk development candidates, dramatically cut down on time and discovery costs. At Ignite, we are committed to innovate in ares that provide a direct solution to problems facing patients and our healthcare system.
Development
Once we have licensed a candidate, Ignite leverages its vast network of partners to facilitate development and market approval. Our organization only pursues and develops candidates that meet the highest standards of accuracy, efficacy, and safety in very defined areas of unmet medical need. Above all, our development is focused on the needs of our healthcare system and people with a direct goal to remove waste, improve quality-of-life and optimize patient outcomes.
Areas of Interest
Initial therapeutic areas of interest include the following:
Immunology
Inflammatory Bowel Disease
Rheumatoid Arthritis
Psoriasis/Psoriatic Arthritis
Substance use
Behavioral health
